The Latest
-
Getty Images
Q&AIs AI finally proving its worth in drug R&D?
A Tufts analysis found that an AI clinical monitoring agent could deliver up to $21 million in value for a late-stage program in oncology R&D. But will the findings apply in more therapeutic areas?
-
Getty Images
Q&ALegend’s interim CEO sees a shorter path to the next era of CAR-T
Alan Bash explains how Carvykti informed the company’s strategy and what its in vivo platform still needs to prove.
-
Permission granted by Tyra Biosciences
Tyra’s one-drug, three-indication bet nears its first phase 2 test
What started as two neighbors trading shop talk has grown into Tyra Biosciences, a clinical-stage biotech company with a blockbuster potential pipeline.
-
Getty Images
Moderna and Merck’s cancer vaccine clears phase 3; Ultragenyx lands gene therapy nod
A personalized mRNA therapy met two melanoma trial goals, the FDA cleared the first treatment for GSDIa, and Novo tests lower doses of its obesity pill.
-
Claudio Ventrella via Getty Images
3 potential blockbusters beyond obesity to watch
Late-stage drugs in pancreatic cancer, multiple myeloma and Alzheimer’s could pair treatment advances with major commercial upside.
-
Getty Images
OpinionThe scientific research pharma leaders keep sharing — and why
Six industry leaders share the scientific papers they keep circulating, spanning transplants, MASH, cancer, real-world evidence and trial design.
-
Getty Images
How cost and perception could reshape the GLP-1 market
As Eli Lilly and Novo Nordisk race for share, surveys show affordability and prescribing preferences may help decide the winners.
-
Sarah Silbiger via Getty Images
Trump nominates policy aide Overton to lead FDA
Heidi Overton, a medical doctor and veteran of the America First think tank, currently serves as deputy director of the White House Domestic Policy Council.
Updated Aug. 19, 2026 -
Permission granted by Courtesy of Helus Pharma
Q&A // First 90 DaysHow Helus’ new CEO plans to scale its psychedelic drug pipeline
Can Michael Halstead replicate the controlled growth he pulled off at Intra-Cellular Therapies in mental health’s psychedelic era?
-
Getty Images
FDA nod is just the first hurdle for Moderna’s potential blockbuster flu vax
Strain selection timing and mRNA skepticism could limit the impact of Moderna’s game-changing mRNA flu shot.
-
Sean Gallup / Staff via Getty Images via Getty Images
BioNTech’s oncology pivot comes with a new CEO
Guido Oelkers will inherit a deep cancer pipeline, declining vaccine sales and $19 billion to fund the transition.
-
Courtesy of BMS
BMS builds big in Texas; Regeneron backs would-be rival
BMS reveals plans for a new manufacturing hub in Houston, and Regeneron invests in startup developing a Dupixent competitor.
-
Getty Images
Biotech initiatives pick up as more regions race to become hubs
New government funding from Pennsylvania to Kansas City is strengthening biotech hubs — but experts say money alone won’t determine where pharma builds next.
-
Permission granted by Image courtesy of Formation Bio
Profile // First 90 DaysFormation Bio taps Biogen, Pfizer alum to tackle R&D’s ‘boring middle’
Dr. Michael Ehlers bets AI can ease the clinical-development bottleneck — but scaling Formation Bio’s pipeline will also require human judgment.
-
Anna Moneymaker via Getty Images
Trump signs order seeking to upend childhood vaccine schedule
The executive order — which wasn’t accompanied by any new scientific evidence — aims to split the MMR vaccine into three separate shots and revives the administration’s attempt to slim down the immunization schedule.
-
Getty Images
Drugs that missed the mark in pharma’s last earnings round
Why treatments from Alnylam, Merck, AbbVie and Roche stumbled in the last quarter.
-
Getty Images
Did Novo’s phase 3 flop kill the inflammation hypothesis in heart disease?
While a disappointing late-stage readout sent biotech stocks tumbling, all hope may not be lost for the emerging approach to treating cardiovascular events.
-
Sascha Schuermann/Getty Images via Getty Images
Why Big Pharma is chasing the industry’s most-powerful supercomputer
BMS is the latest major drugmaker to tap Nvidia for more computing power, betting that larger models and AI agents can speed drug discovery.
-
Getty Images
Large pharmas skirt tariffs; BMS’ dealmaking drought
Big Pharmas won't get hit new levies on branded drugs; and aside from the megamerger rumors, BMS has had a relatively quiet year for M&A.
-
Finn Gomez / Staff via Getty Images
Erica Schwartz confirmed as next CDC director
Schwartz will step into an agency that has been without a permanent leader for almost a year amid RFK Jr.’s tumultuous tenure as HHS chief.
-
Christopher Furlong / Staff via Getty Images
What the AstraZeneca-BMS rumors reveal about pharma megamergers
Reports of talks were quickly disputed, but the prospect exposed the appeal — and antitrust risks — of combining two pharma giants.
-
Getty Images
FDA allows unique endpoint in rare disease study
Global regulators are allowing the company to use hospitalization as the primary efficacy endpoint in its registration trial for a rare neuromuscular disorder.
-
Permission granted by Merck & Co.
Q&AMerck is pharma’s most patent-exposed company. Now it’s reinventing itself.
Keytruda made Merck an oncology powerhouse, but as the patent cliff looms, its business development leader outlines what’s next.
-
Getty Images
Three potential takeover targets in psychedelics
Lilly’s recent deal to acquire AtaiBeckley gave the field a boost, but other biotechs still need to prove their clinical and commercial potential.
-
Getty Images
Why pharma’s record-setting M&A streak is so unique
Early-stage candidates, mid-sized companies and of course, Chinese assets, are dominating the dealmaking picture this year.
